{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:08:40Z","timestamp":1791216520791,"version":"4.1.0"},"reference-count":31,"publisher":"Japan Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1507\/endocrj.ej13-0483","type":"journal-article","created":{"date-parts":[[2014,3,12]],"date-time":"2014-03-12T23:05:32Z","timestamp":1394665532000},"page":"513-521","source":"Crossref","is-referenced-by-count":6,"title":["Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes"],"prefix":"10.1507","volume":"61","author":[{"given":"Guoyue","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caili","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijing","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqian","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyun","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Ruijin Hospital, Center of Molecular Medicine, Shanghai Institute of Endocrine And Metabolic Diseases, State Key Laboratory of Medical Genomics, Shanghai Jiaotong University Medical School, Shanghai 200025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoming","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Jiangsu 212001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. <i>Nature<\/i> 414: 782-787.","DOI":"10.1038\/414782a"},{"key":"2","unstructured":"2. Goto A, Goto M, Noda M, Tsugane S (2013) Incidence of Type 2 Diabetes in Japan: A Systematic Review and Meta-Analysis. <i>PLoS One <\/i>8:e74699"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Cusi K (2010) The role of adipose tissue and lipotoxicity in the pathogenesis of type diabetes. <i>Curr Diab Rep<\/i> 10:306-315.","DOI":"10.1007\/s11892-010-0122-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Li Y, Xu W, Liao Z, Yao B, Chen X, et al. (2004) Induction of Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients Is Associated With Improvement of &beta;-Cell Function. <i>Diabetes Care<\/i> 27(11):2597-2602.","DOI":"10.2337\/diacare.27.11.2597"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ryan EA, Imes S, Wallace C (2004) Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. <i>Diabetes Care<\/i> 27: 1028-1032.","DOI":"10.2337\/diacare.27.5.1028"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Weng J, Li Y, Xu W, Shi L, Zhang Q, et al. (2008) Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. <i>Lancet<\/i> 371: 1753-1760.","DOI":"10.1016\/S0140-6736(08)60762-X"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Vilsb&oslash;ll T, Holst JJ. (2004) Incretins, insulin secretion and type 2 diabetes mellitus. <i>Diabetologia<\/i> 47:357-366.","DOI":"10.1007\/s00125-004-1342-6"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, et al. (2007) Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. <i>Diabetologia<\/i> 50: 1148-1155.","DOI":"10.1007\/s00125-007-0633-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, et al. (2013) Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. <i>Diabetes Obes Metab<\/i> 15(3): 252-257.","DOI":"10.1111\/dom.12020"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, et al. (2009) Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. <i>Diabetes Obes Metab<\/i> 11: 1145-1152.","DOI":"10.1111\/j.1463-1326.2009.01124.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yki-J&auml;rvinen H, Rosenstock J, Dur&aacute;n-Garcia S, Pinnetti S, Bhattacharya S, et al. (2013) Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes<i>. Diabetes Care<\/i> 36: 3875-3881.","DOI":"10.2337\/dc12-2718"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Vilsboll T, Rosenstock J, Yki-Jarvinen H et al.(2010) Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. <i>Diabetes Obes Metab<\/i> 12: 167-177.","DOI":"10.1111\/j.1463-1326.2009.01173.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Katsuno T, Ikeda H, Ida K, Miyagawa J, Namba M. (2013) Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. <i>Endocr J<\/i> 60(6): 733-742.","DOI":"10.1507\/endocrj.EJ12-0293"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hong ES, Khang AR, Yoon JW, Kang SM, Choi SH, et al. (2012) Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. <i>Diabetes Obes Metab<\/i> 14: 795-802.","DOI":"10.1111\/j.1463-1326.2012.01600.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Wajchenberg BL (2007) &beta;-cell failure in diabetes and preservation by clinical treatment. <i>Endocrine Reviews<\/i> 28(2): 187-218.","DOI":"10.1210\/10.1210\/er.2006-0038"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. <i>N Engl J Med<\/i> 359(15): 1577-1589.","DOI":"10.1056\/NEJMoa0806470"},{"key":"17","unstructured":"17. Mozdzan M, Mozdzan M, Loba J, Markuszewski L, Ruxer J (2006) Effect of short-term intensive insulin therapy on daily insulin requirement in poorly controlled type 2 diabetes patients. <i>Wiad Lek <\/i>59:203-207."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, et al. (2004) A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. <i>Diabetes Care<\/i> 27(7): 1554-1558.","DOI":"10.2337\/diacare.27.7.1554"},{"key":"19","unstructured":"19. Lv WS, Li L, Wen JP, Pan RF, Sun RX, et al. (2013) Comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short-term intensive insulin therapy for poorly controlled type 2 diabetes patients. <i>Int J Endocrinol<\/i> 2013: 614242"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. <i>J Clin Invest<\/i> 116(7): 1802-1812.","DOI":"10.1172\/JCI29103"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Mudaliar S (2013) Choice of early treatment regimen and impact on &beta;-cell preservation in type 2 diabetes. <i>Int J Clin Pract<\/i> 67(9):876-887.","DOI":"10.1111\/ijcp.12154"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, et al. (2000) Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. <i>Proc Natl Acad Sci U S A<\/i> 97(12): 6874-6879.","DOI":"10.1073\/pnas.120069197"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, et al. (2011) Mechanisms of action of the DPP-4 inhibitor vildagliptin in man. <i>Diabetes Obes Metab<\/i> 13: 775-783.","DOI":"10.1111\/j.1463-1326.2011.01414.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ahren B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, et al. (2009) Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. <i>J Clin Endocrinol Metab<\/i> 94: 1236-1243.","DOI":"10.1210\/jc.2008-2152"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care<\/i> 35: 1364-1379.","DOI":"10.2337\/dc12-0413"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, et al. (2006) Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. <i>J Clin Endocrinol Metab<\/i> 91(11): 4612-4619.","DOI":"10.1210\/jc.2006-1009"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Cryer PE (2002) Hypoglycaemia: the limiting factor in the glycaemic man-agement of Type I and Type II diabetes. <i>Diabetologia<\/i> 45(7): 937-948.","DOI":"10.1007\/s00125-002-0822-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Christensen M, Vedtofte L, Holst JJ, Vilsb&oslash;ll T, Knop FK (2011) Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. <i>Diabetes<\/i> 60(12): 3103-3109.","DOI":"10.2337\/db11-0979"},{"key":"29","unstructured":"29. Ahr&eacute;n B, Foley JE, Bosi E. (2011) Clinical evidence and mechanistic basis for vildagliptin&rsquo;s action when added to metformin. <i>Diabetes Obes Metab<\/i> 13(3): 193-203."},{"key":"30","unstructured":"30. Woehrle HJ, Neubacher D, Patel S, von Eynatten M (2012) Safety and efficacy of linagliptin plus basal insulin combination therapy in a vulnerable population of elderly patients (age &ge;70 years) with type 2 diabetes. Poster presented at the 48th Annual Meeting of the European Associa-tion for the Study of Diabetes; October 1-5; Berlin, Germany."},{"key":"31","unstructured":"31. Patel S, Schernthaner G, Barnett AH, Emser A, von Eynatten M, et al. (2012) Safety and efficacy of linagliptin in elderly patients with type 2 diabetes: evidence from 1331 individuals aged &ge;65 years [abstract]. <i>Diabetolo-gia<\/i> 55(Suppl 1): S351."}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/61\/5\/61_EJ13-0483\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:40:43Z","timestamp":1618296043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/61\/5\/61_EJ13-0483\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej13-0483","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}